Oxford Sciences Innovation

The world’s largest university-partnered venture firm, investing in early-stage life science, AI & software, healthcare, and deep tech.

4.0
(1)
Add your review

Independent rating of Oxford Sciences Innovation VC fund

Overall rating:
4.0
(1)
Team quality
5.0
Professionalism
Personal qualities
None
Integrity
None
Respect and decency
None
Experience
None
Relevant expertise
None
Investment process
4.5
Approachability
Clarity of the process
None
Speed of the process
Responsiveness
Ease of the process
None
Due diligence
Value add
2.5
Supportiveness
Value add beyond financing
Board activity
Terms
Founder friendly
None
Help with follow-up rounds
None

About Oxford Sciences Innovation VC fund

Website:
https://www.oxfordsciencesinnovation.com/
Founded:
2015
Number of funds:
2
Number of investments:
101
Number of exits:
6
Headquarters:
Oxford, United Kingdom
Organization type:
Venture Capital

How Oxford Sciences Innovation VC fund invests

Rounds:
Venture Round, Series A, Series B, Series C
Average ticket size:
15.9M USD
Biggest investment:
48M USD
Would lead round:
Yes
Would coinvest:
Yes
Countries where invested:
United Kingdom, United States
Sectors of interest:
Medical, Health Care, Biotechnology, Pharmaceutical, Biopharma, Therapeutics, Life Science, Health Diagnostics, Software, Medical Device, Manufacturing, Genetics, Computer Vision, Artificial Intelligence

Portfolio - latest investments by Oxford Sciences Innovation VC fund
Ultromics
Vaccitech
Orbit Discovery
Genomics
Pepgen
Caristo Diagnostics
Oxford Endovascular
Evox Therapeutics
Rey
SpyBiotech

Founders' reviews of Oxford Sciences Innovation VC fund

Team quality
5.0
Professionalism
Investment process
4.5
Approachability
Speed of the process
Responsiveness
Due diligence
Value add
2.5
Supportiveness
Value add beyond financing
Board activity
Terms
Older than a year by portfolio founder
Round: Series A
Beware the Turbulance
OSI has struggled from shareholder wrangling (it's a company not a fund) and internal tensions. If forced to choose between a portfolio company and the University it'll go with the University. Today it is mostly a life sciences VC, and it lacks expertise in other segments. It's not clear what its investment thesis is.
Similar funds